Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2006

AC Immune and Genentech Ink Alzheimer’s Research Agreement Worth Up to $300M

  • AC Immune and Genentech will work together to develop anti-beta-amyloid antibodies for Alzheimer’s and other human diseases, under an exclusive global license agreement and research collaboration . AC Immune has developed conformation-specific antibodies against beta-amyloid generated by its SupraAntigen™ technology.

    Under the terms of this agreement, Genentech will provide funding for a multiyear collaborative research program and will cover all development and clinical costs of the lead antibody and subsequent antibody candidates. Genentech will make an upfront payment with the potential for a total of over $300 million in payments upon successful completion of clinical and regulatory milestones. Upon commercialization of a product, Genentech will pay AC Immune royalties on net sales of AC Immune’s antibodies.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »